Trial Profile
To evaluate sunitinib efficacy and tolerability in panNETs patients treated in a real-world setting
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 20 Sep 2018
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary)
- Indications Neuroendocrine tumours
- Focus Adverse reactions; Therapeutic Use
- 20 Sep 2018 New trial record